Edesa Biotech Inc (EDSA)
$4.37
+0.02
(+0.46%)▲
Performance
- $4.36$4.50$4.37
0.23%
Downside
Day's Volatility :3.11%
Upside
2.89%
- $2.46$8.33$4.37
43.7%
Downside
52 Weeks Volatility :70.48%
Upside
47.56%
Returns
| Period | Edesa Biotech Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -4.79% | 0.0% |
6 Months | 0.46% | 0.0% |
1 Year | -27.32% | 0.0% |
3 Years | -89.11% | -22.3% |
Highlights
Market Capitalization | 14.2M |
Book Value | $0.88 |
Earnings Per Share (EPS) | -19.87 |
Wall Street Target Price | 20.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -71.52% |
Return On Equity TTM | -129.29% |
Revenue TTM | 500.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -99.9% |
Gross Profit TTM | 311.2K |
EBITDA | -8.3M |
Diluted Eps TTM | -19.87 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.15 |
EPS Estimate Next Year | -1.93 |
EPS Estimate Current Quarter | -0.58 |
EPS Estimate Next Quarter | -0.52 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 369.11%
Technicals Summary
Sell
Neutral
Buy
Edesa Biotech Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Edesa Biotech Inc | -8.96% | 0.46% | -27.32% | -89.11% | -87.85% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Edesa Biotech Inc | NA | NA | NA | -2.15 | -1.29 | -0.72 | NA | 0.88 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Edesa Biotech Inc | Buy | $14.2M | -87.85% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Edesa Biotech Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 64.4%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 158.3%
Institutional Holdings
CM Management, LLC
2.77%Vanguard Group Inc
0.49%Geode Capital Management, LLC
0.44%Dimensional Fund Advisors, Inc.
0.35%Tower Research Capital LLC
0.06%Royal Bank of Canada
0.05%
Company Information
founded in 2015, edesa biotech brings innovative new treatments for dermatological and anorectal diseases. late-stage prescription drugs developed by edesa biotech aim to help patients who experience limited treatment options. edesa biotech's focus on dermatology is led by an experienced team that have licensed global rights to clinical stage assets for dermatology and anorectal indications.
Organization | Edesa Biotech Inc |
Employees | 16 |
CEO | Dr. Pardeep Nijhawan FRCPC, M.D. |
Industry | Biotechnology |
Discover More
A Spac I Acquisition Corp
$4.37
+0.46%
Keyarch Acquisition Corp
$4.37
+0.46%
Connexa Sports Technologies Inc
$4.37
+0.46%
Us Value Etf
$4.37
+0.46%
First Wave Biopharma Inc
$4.37
+0.46%
Global X Msci Next Emerging
$4.37
+0.46%
Fat Projects Acquisition Corp
$4.37
+0.46%
Capital Link Global Fintech
$4.37
+0.46%
Applied Uv Inc
$4.37
+0.46%